Full-Time

Medical Science Liaison

Uro-Oncology, New York

Updated on 9/3/2026

Deadline 9/15/26
Ferring Pharmaceuticals

Ferring Pharmaceuticals

5,001-10,000 employees

Develops peptide hormone-based medicines and therapies

Compensation Overview

$174.9k - $200k/yr

+ Bonus

Parsippany-Troy Hills, NJ, USA

In Person

Field-based role with travel 60%+; on-site in Parsippany, NJ.

PharmD, PhD, MD

Category
Medical, Clinical & Veterinary

Get referred to Ferring Pharmaceuticals

See people who can refer or advise you

Requirements
  • Doctorate degree (D.V.M., M.D., Ph.D. or Pharm.D) in biological sciences
  • Minimum of 2 years previous MSL Experience
  • Experience in Uro-Oncology, Urology or Oncology required as a practicing MSL
  • Ability to apply technical expertise and solutions to diverse/individualized situations
  • Excellent communication & presentation skills
  • Working knowledge of FDA and OIG requirements as well as clinical trial design and statistics is required
  • Teamwork skills and an ability to work effectively with a variety of colleagues
  • Networking skills and the confidence to interact with senior experts on a peer-to-peer level
  • Critical data analysis skills
  • Willingness to keep up to date with scientific literature
  • High level of emotional intelligence to work effectively with stakeholders
  • Represents the organization as a prime field medical contact
  • Field-based role. Willingness to travel 60 % or more of the time
Responsibilities
  • Present healthcare professionals and decision makers with accurate, unbiased, balanced and timely answers to unsolicited request for information about bladder cancer
  • Establish scientific and clinical relationships with key opinion leaders and academic centers to expand research and educational opportunities in Uro-Oncology/Bladder Cancer
  • Provide study support from protocol and budget development to submission and completion for Phase IV as well as Investigator Initiated Trials (IIT’s)
  • Provide continuing field scientific support and training for sales and Corporate Account Managers (CAM’s)
  • Document and forward reports of adverse events to appropriate personnel
  • Keep abreast of medical and scientific developments in assigned therapeutic area
  • Proactively report competitive activities as well as events that can influence the use of product(s)
  • Develop and deliver scientific/educational programs including but not limited to formulary presentations for managed care and related organizations
  • Assist Medical Affairs as well as agency personnel in the development of presentations and slide kits
  • Actively participate in advisory boards, speaker training events, clinical investigator meetings, regional national and international meetings when required
  • Assist in processing of field request for medical education funding
  • Participate in key medical and scientific conferences by staffing medical information booths; gathering competitive intelligence on competitors and attending scientific sessions
Ferring Pharmaceuticals

Ferring Pharmaceuticals

View

Ferring Pharmaceuticals develops medicines that use the body's own peptide hormones, focusing on specialties such as reproductive health, gastroenterology, and urology. Its products range from hormone-based therapies to newer gene-based treatments, such as Adstiladrin for bladder cancer. The company achieves its solutions through research-driven development and manufacturing, including synthetic production of peptide hormones (historically oxytocin and vasopressin) and ongoing expansion of production and clinical programs. Ferring differentiates itself by remaining privately held to pursue a long-term research vision, growing through organic expansion and strategic acquisitions while maintaining a global footprint (over 100 countries, 7,000+ employees). Its goal is to advance therapies that leverage the body's biology to treat diseases more effectively, supported by a sustained investment in R&D and manufacturing, with a future focus on bioengineered and gene-based approaches.

Company Size

5,001-10,000

Company Stage

Debt Financing

Total Funding

$302.5M

Headquarters

Saint-Prex, Switzerland

Founded

1950

Get referred to Ferring Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved ADSTILADRIN label update in July 2026, improving workflow and usability.
  • March 2026 NCCN upgraded ADSTILADRIN for papillary tumors, widening physician adoption.
  • STIMATE returns in October 2026 and restores an inherited rare-disease revenue stream.

What critics are saying

  • Ferring cut 500 jobs in 2025-2026, signaling margin pressure and reorganization fatigue.
  • ADSTILADRIN remains the growth bet; failure to expand uptake weakens Ferring’s portfolio.
  • Combining Paulsen’s chairman and CEO roles in February 2026 centralizes power and key-person risk.

What makes Ferring Pharmaceuticals unique

  • Ferring owns ADSTILADRIN, one of few intravesical gene therapies for bladder cancer.
  • Ferring still sells fertility, gastroenterology, and urology brands in 100-plus countries.
  • Jean-Frédéric Paulsen’s 2025 enterprise model concentrates capital on mid- to late-stage assets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Disability Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Tuition Reimbursement

Paid Sick Leave

Paid Vacation

Paid Holidays

Parental Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

7%

2 year growth

7%
PR Newswire
Sep 1st, 2026
RedHill acquires Ferring's Rebyota and Clenpiq for $12M, completing strategic repositioning

RedHill Biopharma has acquired exclusive commercialization rights to Ferring Pharmaceuticals' Rebyota and Clenpiq for $12 million upfront, plus potential milestones and tiered royalties. The two FDA-approved gastrointestinal drugs generated approximately $37.5 million in combined US net sales in 2025. Rebyota, a single-dose treatment for preventing recurrent C. diff infection approved in 2022, generated $16.9 million in 2025 US sales. Clenpiq, a ready-to-use bowel preparation, generated $20.6 million with minimal promotion. The acquisition is fully funded through RedHill's previously announced $18 million Talicia divestment. The transaction completes RedHill's strategic repositioning of its commercial gastrointestinal business, providing the company with a materially larger commercial operation and stronger liquidity position. RedHill obtained global commercialization rights for Rebyota and US rights for Clenpiq.

Hemophilia Federation of America
Jul 30th, 2026
Nasal spray STIMATE returning to market this fall.

Nasal spray STIMATE returning to market this fall. * July 29, 2026 Ferring Pharmaceuticals has announced their nasal spray STIMATE will return to the market this fall following a six year absence. The nasal spray for Hemophilia A and von Willebrand Type 1 patients was voluntarily recalled in 2020 due to what the pharmaceutical company called a "packaging-related issue, which has now been resolved." Ferring announced in a letter to the community the FDA had approved STIMATE's return to the market in early July 2026, and that the product will become available to patients in October. The full letter is available here.

New Zealand Society of Gastroenterology
Jul 6th, 2026
Register for the Motility Symposium - 18 september 2026.

Register for the Motility Symposium - 18 september 2026. Posted Monday July 6, 2026 A great day is planned for the 2026 Motility Symposium including sessions on Upper GI and Gastric, Mid/Lower Tract Physiology & Endoscopy, and Systemic * Psychogastroenterology. See the full programme below. Registration for the event is $520.00 and incudes a dinner following the symposium at Ayrburn. Gallery. Monday July 6, 2026 Demo Content Events + 1 More In late July the NZSG Executive Committee will be meeting to consider the Strategic Plan for 2027 to 2032 Monday July 6, 2026 Demo Content Events The 2026 NZSG IBD Symposium is proudly sponsored by Pharmaco and Ferring, taking place in Wellington. Monday July 6, 2026 Demo Content Gastroenterologists across Aotearoa are welcome to participate in a national validation study evaluating an AI assisted...

PharmiWeb
May 19th, 2026
Cosette Pharmaceuticals appoints David Bell as Chief Commercial Officer (Brands).

Cosette Pharmaceuticals appoints David Bell as Chief Commercial Officer (Brands). - Proven biopharmaceutical executive to lead commercial strategy as Cosette scales its branded pharmaceutical platform and advances its next phase of growth - BRIDGEWATER, N.J.-(BUSINESS WIRE)-#cosettepharma-Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today it has appointed David Bell as Chief Commercial Officer (Brands). David joins the company's executive leadership team as it continues to advance its ambitions in specialty pharmaceuticals and expand its commercial platform and portfolio. In this new role, David will oversee all branded commercial functions - including sales, marketing, market access, commercial operations, analytics, and portfolio strategy. He will be responsible for driving performance across Cosette's marketed portfolio of 21 brands, supporting the integration and growth of acquired assets, and ensuring strong alignment between commercial execution and the company's broader strategic and financial objectives. "David's appointment reflects Cosette's continued investment in the commercial capabilities required to support the next level of growth," said Apurva Saraf, President and CEO of Cosette Pharmaceuticals. "His deep expertise in commercial strategy, market access, portfolio management, and P&L leadership will be valuable as we continue to strengthen our branded portfolio and integrate new assets." David brings more than 25 years of commercial and enterprise leadership experience across oncology, rare disease and gene therapy in specialty pharmaceuticals markets. Most recently, David served as Vice President, Business Unit Head, US Oncology at Ferring Pharmaceuticals, where he held full U.S. P&L ownership responsibility. He also previously served as Franchise General Manager at Melinta Therapeutics and spent 17 years at Merck & Co. / Schering-Plough in progressive global, U.S., and regional commercial leadership roles. "I am proud to join Cosette, an organization that has built a differentiated platform with brands that help patients live better lives," David shared. "I am excited to join a leadership team that will take Cosette's branded portfolio to the next phase of corporate growth by maximizing current and acquired assets, expanding patient access to important medicines, and alleviating the burden and suffering of patients and their families." David earned his Master of Business Administration and Bachelor of Science in Finance from Seton Hall University's W. Paul Stillman School of Business. He also served as a board member of Enhanced HealthCare Solutions. About Cosette Pharmaceuticals Cosette Pharmaceuticals, Inc. is a U.S.-based, leading specialty pharmaceutical company providing some of the most trusted and well-known brands in medicine - developing and delivering products that make a difference in patients' lives. Cosette's strong growth has been driven by its best-in-class marketing, promotion, and strategic distribution capabilities, enabling the company to scale efficiently while continuing to invest in high-quality, patient-centered therapies. Cosette has corporate headquarters in Bridgewater, New Jersey and is supported by 350+ dedicated team members across all functional areas. Cosette is backed by Avista Healthcare Partners, a healthcare focused private equity firm, and funds managed by Hamilton Lane, a private markets investment management firm (Nasdaq: HLNE). For more information, please visit www.cosettepharma.com or follow Cosette on LinkedIn. Editor details. * Company: * Businesswire Last Updated: 19-May-2026

Contract Pharma
May 19th, 2026
Cosette Pharmaceuticals names David Bell CCO of brands.

Cosette Pharmaceuticals names David Bell CCO of brands. Bell is tasked with driving performance across Cosette's marketed portfolio of 21 brands. May 19, 2026 Content Marketing Editor Why This Matters: See our industry-wide coverage of other executive team appointments and promotions here. Cosette Pharmaceuticals is appointing David Bell Chief Commercial Officer (CCO), Brands. Accordingly, Bell will oversee commercial functions for all 21 brands in Cosette's marketed portfolio. This includes sales, marketing, market access, commercial operations, analytics, and portfolio strategy among areas in which Bell will drive performance. According to Cosette, Bell will support integration and growth of acquired assets as the company advances commercial ambitions in specialty pharmaceuticals. Overseeing commercial performance of brands. In the CCO role, Bell will ultimately oversee alignment between Cosette's commercial execution and its broader strategic and financial objectives. "I'm proud to join an organization that has built a differentiated platform [to] help patients live better lives," Bell said. He emphasized his excitement in taking Cosette "to the next phase of corporate growth by maximizing current and acquired assets." "David's appointment reflects Cosette's continued investment in commercial capabilities required to support the next level of growth." Apurva Saraf, President and CEO, Cosette Pharmaceuticals Bell also mentioned the importance of expanding patient access to key medicines, and alleviating patient and family burdens and suffering. Cosette President and CEO Apurva Saraf said the appointment reflects the company's investment in commercial capabilities to support next-level growth. "[Bell's] deep expertise in commercial strategy, market access, portfolio management, and P&L leadership will be valuable," Saraf said. "We continue to strengthen our branded portfolio and integrate new assets." New Cosette CCO's experience. Bell most recently served as Vice President, Business Unit Head, U.S. Oncology at Ferring Pharmaceuticals. There, he held full P&L ownership responsibility in the United States. He was also General Manager at Melinta Therapeutics. Prior to that, Bell spent 17 years at Schering-Plough/Merck & Co., holding regional, U.S., and global commercial leadership roles. He has additionally served as a board member of Enhanced HealthCare Solutions. Altogether, Bell brings to Cosette more than a quarter-century of leadership experience in oncology, rare disease, and gene therapy.